Bellicum Pharmaceuticals, Inc. (BLCM)

Oncology Corporate Profile

Stock Performance

12.1800
0.0000

HQ Location

6400 Fannin Street, Suite 2300
Houston, TX 77030

Company Description

Bellicum Pharmaceuticals, Inc. is developing clinical applications of chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered. Bellicum's mission is to leverage this smart technology to bring safe, effective, innovative cell therapies to market for patients with serious and life threatening diseases. The company's DeCIDe™ vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific T cell immune response. Lead product BPX-101, an autologous DeCIDe™ vaccine, is in clinical development for patients with metastatic castrate resistant prostate cancer (mCRPC). CaspaCIDe™ is a cell therapy safety switch, permitting the rapid elimination of cells in the event of toxicity. CaspaCIDe™ DLI is a donor lymphocyte infusion administered following a hematopoietic stem cell transplant, in which the safety switch may be activated to resolve graft-versus-host disease (GVHD).

Website: http://www.bellicum.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BPX-501immunotherapyVarious cancer typesII
AP 1903gene targeted drug using Argent systemSupportive CareIAriad
DeCIDe_ / BPX-101immunotherapy1st line metastatic castrate-resistant Prostate cancer (CRPC)I

View additional information on product candidates here »

Pipeline image

Source


http://www.bellicum.com/

Recent News Headlines

Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

3/23/2017 10:02 pm

[GlobeNewswire] - HOUSTON, March 23, 2017-- Bellicum Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $12.00 per share. ...

Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock

3/22/2017 08:00 pm

[GlobeNewswire] - HOUSTON, March 22, 2017-- Bellicum Pharmaceuticals, Inc. today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. Bellicum expects to grant the underwriters ...

Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

3/13/2017 08:00 pm

[GlobeNewswire] - On track to complete enrollment in E.U. registration trials for BPX-501 and rimiducid this year. Reported updated clinical data with BPX-501 demonstrating rapid immune recovery and low rates of GvHD in ...

Bellicum Pharmaceuticals to Present at the Barclays Global Healthcare Conference

3/8/2017 12:00 pm

[GlobeNewswire] - HOUSTON, March 08, 2017-- Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick ...

Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017

3/6/2017 12:00 pm

[GlobeNewswire] - HOUSTON, March 06, 2017-- Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the ...

Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers

2/22/2017 09:01 pm

[GlobeNewswire] - HOUSTON, Feb. 22, 2017-- Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the presentation ...

Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate

2/21/2017 12:00 pm

[GlobeNewswire] - HOUSTON, Feb. 21, 2017-- Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced it has dosed ...

Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth

1/31/2017 12:00 pm

[GlobeNewswire] - HOUSTON, Jan. 31, 2017-- Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited ...